B. Oksuzoglu

Risk Factors for Stage IV Breast Cancer at the Time of Presentation in Turkey

BACKGROUND Breast cancer (BC) is the one of the most common cancers in women. It is also a leading cause of death. Unfortunately, some patients initially present with distant metastases and are diagnosed with stage IV disease that is nearly always, by then, incurable. This retrospective analysis investigated the risk factors for stage IV BC that may underlie such late presentation. MATERIALS AND METHODS In all, 916 patients with BC who visited the medical oncology polyclinic of eight different centres in Turkeybetween December 2011 and January 2013 were analysed. RESULTS A total of 115 patients (12.6%) presented with stage IV disease. In univariate analysis; to comparing these with patients at other stages, no statistical difference was found for median diagnosis age or age at menarche (p=0.611 and p=0.820), whereas age at menopause and age at first live birth were significant (p=0.018 and p=0.003). No difference was detected in terms of accompanying diseases, use of oral contraceptives and hormone replacement therapy, smoking, alcohol consumption and the rate of family history of BC between the patients (p=0.655, p=0.389, p=0.762, p=0.813, p=0.229, p=0.737). However, screening methods were employed less often, the rate of illiteracy was higher, and the rate of other cancers was higher in patients with stage IV BC (p=0.022, p=0.022, p=0.018). No statistical difference was observed between the patients in terms of tumour histopathology, and status of oestrogen receptor, progesterone receptor, or human epidermal growth factor-2 receptor (p=0.389, p=0.326, p=0.949, p=0.326). Grade 3 tumours were more frequent in patients with stage IV disease (p<0.001). On multivariate analysis, risk factors for stage IV breast cancer at the time of presentation were found to be age at first live birth and educational level (p=0.003 and p=0.047). CONCLUSIONS Efforts should be made to perform mammography scans, in particular, at regular intervals through national training programs for all women, particularly those with family histories of breast and other types of cancer, and to establish early diagnosis of BC long before it proceeds to stage IV. Additionally, womens education had better be upgraded. In order to make women aware of BC, national education-programmes must be organised.

672PA RETROSPECTIVE EVALUATION OF EFFICACY AND TOLERABILITY OF TWO DIFFERENT ADJUVANT CHEMORADIOTHERAPY REGIMENS IN OPERABLE NODE-POSITIVE GASTRIC CARCINOMA WITH D2 LYMPH NODE DISSECTION

ABSTRACT Aim: Optimal adjuvant treatment in gastric cancer (GC) patients (pts) with D2 lymph node dissection (D2LND) is still undefined. The aim of this retrospective study was to evaluate the efficacy and tolerability of two different adjuvant chemoradiotherapy (ACRT) regimens in operable node-positive GC pts with D2LND. Methods: 138 curatively resected GC pts who underwent D2LND and had node-positive disease were included in this study. They received ACRT between January 2006 and March 2013 in Ankara Oncology Hospital. Pts treated with Intergroup 0116 ACRT protocol were named as arm A (54.3%, n = 75). Pts received biweekly cisplatin (50 mg/m2 on day 1) plus infusional 5-fluorouracil/folinic acid (CFF) and radiation therapy concurrent with bolus 5-FU were included in arm B (45.7%, n = 63). Also, the study population was divided into two different subgroups: Pts who completed all planned ACRT (75.4%, n = 104), and pts who did not complete the planned ACRT in spite of dose reduction and/or delaying and best supportive care (24.6%, n = 34 ). Results: Median follow-up was 30 ( range:6-120) months(mts). Completion rate of ACRT: 80% for arm A and 70% for arm B (p = .23). Grade 3-4 toxicity rate was greater in group B than group A (32.4% vs 67.6%, p Conclusions: Adjuvant CFF plus CRT are not able to change the prognosis of pts who had lymph node-positive GC with D2LND even if receiving for N3 disease and diffuse histology, but toxicity is increased by the treatment . Completion of ACRT is the more important predictor for survival in curatively resected GC. Disclosure: All authors have declared no conflicts of interest.